Post-injury treatment with GM1 ganglioside reduces nociceptive behaviors and spinal cord metabolic activity in rats with experimental peripheral mononeuropathy.
In a rat model of painful peripheral mononeuropathy, this study examined the effects of post-injury treatment with a monosialoganglioside, GM1, on abnormal nociceptive behaviors and spinal cord neural activity resulting from loose ligation of the rat common sciatic nerve (chronic constrictive injury, CCI). Thermal hyperalgesia and spontaneous pain behaviors of CCI rats were assessed by measuring foot-withdrawal latencies to radiant heat and by rating spontaneous hind paw guarding positions, respectively. Neural activity within different regions of the spinal cord was inferred in both CCI and sham-operated rats by employing the [14C]-2-deoxyglucose (2-DG) autoradiographic technique to measure spinal cord glucose metabolism. Intraperitoneal (i.p.) GM1 treatment (10 mg/kg) initiated 1 h or 24 h after injury and once daily for the first 9 post-injury days reduced thermal hyperalgesia of the hind paw ipsilateral to nerve ligation and lowered spontaneous pain behavior rating scores in CCI rats. Sciatic nerve ligation reliably increased basal 2-DG metabolic activity of CCI rats in all four sampled regions (laminae I-IV, V-VI, VII, VIII-IX) of spinal cord lumbar segments (L2-L5) both ipsilateral and contralateral to nerve ligation 10 days after injury. Consistent with the drug's effects on spontaneous pain behaviors, 10 daily GM1 treatments (10 mg/kg, i.p.) initiated 1 h after nerve ligation reduced spinal cord 2-DG metabolic activity in laminae V-VI and VII ipsilateral to nerve ligation and in all four sampled regions contralateral to nerve ligation. This attenuation of the increased spinal cord glucose utilization that occurs in the absence of overt peripheral stimulation may reflect an influence of GM1 on increased neural activity contributing to spontaneous pain. Since gangliosides are thought to protect neurons from excitotoxic effects of excitatory amino acids, these results suggest that ganglioside treatment may result in attenuation of excitatory neurotoxicity that may occur following peripheral nerve injury. Thus, ganglioside treatment could provide a new approach to the clinical management of neuropathic pain syndromes following peripheral nerve injury.
Mao
J
J
Department of Physiology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.
Hayes
R L
RL
Price
D D
DD
Coghill
R C
RC
Lu
J
J
Mayer
D J
DJ
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D005260:Female; D005677:G(M1) Ganglioside / Q000627:therapeutic use*; D005947:Glucose / Q000378:metabolism; D010146:Pain / Q000517:prevention & control* / Q000523:psychology; D010147:Pain Measurement; D010523:Peripheral Nervous System Diseases / Q000503:physiopathology*; D051381:Rats; D011919:Rats, Inbred Strains; D012584:Sciatic Nerve / Q000293:injuries* / Q000473:pathology; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology
D005677:G(M1) Ganglioside; D005947:Glucose